UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.2900 -0.0200 (-1.53%) 04/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.2900 unch (unch) 19:58 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.2700
Day High
1.4000
Open 1.3200
Previous Close 1.3100 1.3100
Volume 1,810,400 1,810,400
Avg Vol 1,155,730 1,155,730
Stochastic %K 83.72% 83.72%
Weighted Alpha -29.09 -29.09
5-Day Change +0.1600 (+14.16%) +0.1600 (+14.16%)
52-Week Range 0.7720 - 1.8400 0.7720 - 1.8400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,010
  • Shares Outstanding, K 90,847
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,880 K
  • EBIT $ -32 M
  • EBITDA $ -32 M
  • 60-Month Beta 2.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.00

Options Overview Details

View History
  • Implied Volatility 127.27% ( +7.43%)
  • Historical Volatility 62.16%
  • IV Percentile 34%
  • IV Rank 25.43%
  • IV High 369.63% on 04/07/25
  • IV Low 44.61% on 05/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3,539
  • Volume Avg (30-Day) 1,603
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 86,217
  • Open Int (30-Day) 98,027

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +475,814.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9500 +35.79%
on 04/07/25
Period Open: 1.2000
1.4000 -7.86%
on 04/21/25
+0.0900 (+7.50%)
since 03/21/25
3-Month
0.8505 +51.68%
on 01/23/25
Period Open: 1.1500
1.8400 -29.89%
on 02/03/25
+0.1400 (+12.17%)
since 01/21/25
52-Week
0.7720 +67.10%
on 12/13/24
Period Open: 1.5400
1.8400 -29.89%
on 02/03/25
-0.2500 (-16.23%)
since 04/19/24

Most Recent Stories

More News
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

SLS : 1.2900 (-1.53%)
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

SLS : 1.2900 (-1.53%)
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

/CNW/ -- USA News Group News Commentary – Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what's being...

ONCY : 0.5750 (+2.50%)
GNTA : 3.87 (-0.26%)
CELC : 10.45 (+2.05%)
NYT : 48.86 (-0.83%)
SLS : 1.2900 (-1.53%)
ONC.TO : 0.79 (+2.60%)
AMGN : 273.68 (-1.30%)
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

SLS : 1.2900 (-1.53%)
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SLS : 1.2900 (-1.53%)
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SLS : 1.2900 (-1.53%)
SELLAS Announces Key Business Objectives for 2025

SLS : 1.2900 (-1.53%)
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

SLS : 1.2900 (-1.53%)
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SLS : 1.2900 (-1.53%)
SELLAS Life Sciences Reports Promising Data from Phase 2 Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia

SELLAS reports median overall survival over 7.7 months and a 56% overall response rate for AML patients using SLS009.Quiver AI SummarySELLAS Life Sciences Group, Inc. has released promising new data from...

SLS : 1.2900 (-1.53%)

Business Summary

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present...

See More

Key Turning Points

3rd Resistance Point 1.5000
2nd Resistance Point 1.4500
1st Resistance Point 1.3700
Last Price 1.2900
1st Support Level 1.2400
2nd Support Level 1.1900
3rd Support Level 1.1100

See More

52-Week High 1.8400
Fibonacci 61.8% 1.4320
Fibonacci 50% 1.3060
Last Price 1.2900
Fibonacci 38.2% 1.1800
52-Week Low 0.7720

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro